Veloxis CEO expects to close partnership deals this year

The sale of Veloxis’ lead product Envarsus XR is still relatively modest, but plans to enter into a slew of distribution deals should give a much needed growth boost in 2017, while new appointments should also push growth and aid the Danish company’s contact with the US FDA.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Dansk biotekboss rejser 91 mio til at udfordre Novo Nordisk

Et amerikansk biotekselskab, som er grundlagt af en dansk molekylærbiolog, har rejst 91 mio. kr. til at fremme programmer inden for diabetes, fedme og fedtlever, herunder et "transformativt" diabeteslægemiddel rettet mod biologiske mål, som Novo Nordisk også arbejder med.

Related articles